公开(公告)号：US11530261B2

公开(公告)日：2022-12-20

申请号：US16865723

申请日：2020-05-04

Applicant: Novartis AG

Inventor： Feng Cong ,  William Dietrich ,  Nathalie George ,  Dong Liu ,  Asher Schachter ,  Aditi Soni ,  Jing Zhou

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/22 ,  A61K38/18

Abstract: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.

公开(公告)号：US10683346B2

公开(公告)日：2020-06-16

申请号：US15818090

申请日：2017-11-20

Applicant: Novartis AG

Inventor： Feng Cong ,  William Dietrich ,  Nathalie George ,  Dong Liu ,  Asher Schachter ,  Aditi Soni ,  Jing Zhou

IPC: A61K38/18 ,  A61K39/395 ,  A61K39/00 ,  C07K16/22

Abstract: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.

公开(公告)号：US11434269B2

公开(公告)日：2022-09-06

申请号：US16464113

申请日：2017-06-13

Applicant: Novartis AG

Inventor： Feng Cong ,  William Dietrich ,  Nathalie George ,  Dong Liu ,  Asher Schachter ,  Aditi Soni ,  Jing Zhou

IPC: A61K39/00 ,  A61K38/00 ,  C07K14/505 ,  C07K16/22 ,  A61P7/06 ,  A61K38/18

Abstract: The present invention relates methods of treatment using BMP6 antagonists.

公开(公告)号：US20200377603A1

公开(公告)日：2020-12-03

申请号：US16799509

申请日：2020-02-24

Applicant: Novartis AG

Inventor： Feng Cong ,  Seth Ettenberg ,  Felix Hartlepp ,  Ingo Markus Klagge

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to antibodies targeting LRP6 and compositions and methods of use thereof.

公开(公告)号：US20150125857A1

公开(公告)日：2015-05-07

申请号：US14380776

申请日：2013-02-22

Applicant: NOVARTIS AG

Inventor： Feng Cong ,  Huaixiang Hao ,  Mindy Hsin-I Hsieh ,  Xiaomo Jiang ,  Jun Liu ,  Nicholas Ng

IPC: C12Q1/68 ,  G01N33/574 ,  A61K31/497

CPC classification number: C12Q1/6886 ,  A61K31/497 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57438 ,  G01N33/57492 ,  G01N2800/52

Abstract: Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation mutation, phosphorylated LRP6, phophorylated Dishevelleds, and the expression of Frizzleds. These biomarkers can be associated with the better outcome for cancer patients treated with Wnt pathway inhibitors.

Abstract translation: 公开了预测从Wnt拮抗剂的治疗施用中受益的癌症患者的鉴定的生物标志物，方法和测定。 生物标志物包括RNF43和ZNRF3基因缺失的检测，RNF43和ZNRF3 mRNA表达的降低，RNF43和ZNRF3蛋白表达的降低，RNF43和ZNRF3失活突变，磷酸化的LRP6，磷酸化的Dishevelleds和Frizzleds的表达。 这些生物标志物可以与用Wnt途径抑制剂治疗的癌症患者的更好的结果相关联。